Blog

Medical equipment provider delivers on-demand solutions for patients with high BMIs

HOUSTON, TX / ACCESS Newswire / June 25, 2025 / As the nation confronts record-high obesity rates, hospitals are under growing pressure to care for patients with complex, weight-related medical needs. US Med-Equip, a leading provider of rented medical equipment, is helping health systems respond with specialized bariatric equipment and clinical support designed to improve safety, mobility and outcomes for patients with high body mass indexes (BMIs).

More than 42% of U.S. adults are considered obese, according to the Centers for Disease Control and Prevention. Among them, nearly 1 in 10 have a BMI of 40 or higher, qualifying as “severe” or “class III” obesity. These patients often face increased risks for respiratory distress, skin breakdown, and limited mobility. An increasing number of hospitals are responding by turning to US Med-Equip for specialized equipment rentals and support that help them deliver safer, more effective care.

US Med-Equip (USME) is supporting hospitals nationwide with bariatric beds, Advanced WAVE^® therapeutic surfaces, lifts, extra-wide wheelchairs, recliners and other high-capacity equipment built to meet the needs of larger patients.

“Hospitals don’t always know when a patient with bariatric needs will arrive in the ER, but they do know they have to be ready,” said Greg Salario, CEO of US Med-Equip. “We help them respond in those critical moments with equipment that protects both patients and the caregivers at their side.”

Rather than investing in costly equipment that may only be needed intermittently, hospitals are turning to USME to rent bariatric devices and receive 24/7 delivery, setup and support. USME’s clinical teams also provide bedside training and intentional rounding to ensure equipment is properly configured functioning at optimal settings for each patient’s needs.

USME’s bariatric equipment includes:

• Expandable bed frames and therapeutic mattresses with low air loss and pressure redistribution

• Lift and transfer systemsto support safe patient handling and reduce staff injuries

• Reinforced wheelchairs, commodes, and recliners for enhanced comfort and durability

• Respiratory support devices configured for larger patients with compromised breathing

Hospitals count on USME’s teams for critical equipment delivered in two hours plus drive time – faster than anyone else – so their care teams can act without delay when lives are on the line. For more information about US Med-Equip’s bariatric solutions, visit  www.usme.com.

About US Med-Equip:

USME partners with top hospitals to provide the highest quality medical equipment, including monitoring devices, ventilators, infusion pumps, patient beds and more. From on-demand delivery of medical equipment rentals to asset management and onsite biomedical support services, USME is the highest-rated medical equipment partner for hospitals across the country.

Contact Information:

Buse Kayar
busek@accessnewswire.com

SOURCE: US Med-Equip

View the original press release on ACCESS Newswire

Rhode Island manufacturer’s latest environment monitoring solution recognized for exceptional simplicity, ease of use, and seamless integration capabilities

WARREN, RI / ACCESS Newswire / June 25, 2025 / AVTECH Software (AVTECH), the leading provider of network-based environment monitoring solutions, is proud to announce that its Room Alert MAX product line has been selected as a winner of the prestigious 2025 MSP Today Product of the Year Award.

In business for nearly 40 years, AVTECH manufactures Room Alert, the world’s most popular environment monitoring platform for business continuity plans, outage prevention, and workplace safety. Room Alert is made in the USA and proactively monitors environment conditions such as temperature, humidity, heat index, flood, power, smoke, and more. Room Alert is currently used in 187 of 196 countries by organizations ranging from thousands of small businesses to Boeing, Sprint, Microsoft, over 80% of the Fortune 1000, the United Nations, and many government agencies.

Room Alert MAX builds upon AVTECH’s proven foundation as the world’s most popular environment monitor for business continuity plans, outage prevention, and workplace safety. Like all Room Alert products, Room Alert MAX is made in the USA and proactively monitors critical environment conditions in facilities of all types and sizes. The new Room Alert MAX platform delivers these capabilities with unprecedented simplicity, enabling faster deployments and reduced complexity for MSPs managing multiple client installations.

“We are honored to receive this recognition from MSP Today, which validates our focus on creating solutions that not only deliver top of the line environmental monitoring capabilities but also prioritize the user experience,” stated Richard Grundy, President & CEO at AVTECH. “Room Alert MAX was designed to offer a simple setup and seamless integration with our existing product family, giving our customers and valued partners another way to extend proactive environment monitoring throughout their facilities.”

The 2025 MSP Today Product of the Year Award further reinforces AVTECH’s position as a trusted partner in the MSP & reseller community. Each winning solution was carefully judged by the editors of TMC’s MSP Today, and this recognition highlights Room Alert MAX’s ability to address the evolving needs of MSPs who require solutions that are both powerful and easy to deploy across diverse client environments.

“It gives me great pleasure to recognize AVTECH Software as a 2025 recipient of TMC’s MSP Today Product of the Year Award for their innovative solution, Room Alert MAX,” said Rich Tehrani, CEO of TMC. “Our judges were thoroughly impressed not only by the strength and features of the product, but by AVTECH’s commitment to the Channel-empowering partners to deliver exceptional service and drive meaningful results for their clients.”

AVTECH’s Room Alert remains the leading environment monitoring solution for data centers, IT rooms, warehouses, cold storage, and other facilities. AVTECH has been serving customers for almost 40 years and continues to provide innovative solutions that help businesses protect their people, property, and productivity to provide Peace of Mind. For more information please visit AVTECH.com.

About AVTECH

AVTECH Software (AVTECH), a private corporation founded in 1988, is a computer hardware and software developer and manufacturer based in Warren, RI with an international sales office in Dubai, UAE as well as an international distribution facility in Shannon, Ireland. AVTECH’s Room Alert products are made in the USA at their affiliated company Mirian Solutions, and proactively monitor critical facilities and assets for conditions such as temperature, humidity, power, water leaks, smoke and more, providing organizations with 24/7 awareness of their facility environments. Trusted by over 80% of the Fortune 1000, countless government agencies, and the US military, AVTECH and Room Alert protect people, property, and productivity to provide peace of mind.

###

SOURCE: AVTECH Software, Inc

View the original press release on ACCESS Newswire

Lon G. von Hurwitz, who will serve as chief strategist and senior advisor, brings 30-plus years of leadership experience in healthcare innovation, marketing, and public health initiatives and will guide efforts to bring the smart medication delivery technology to market in early 2026.

EDMOND, OKLAHOMA / ACCESS Newswire / June 25, 2025 / PillSafe, a leader in smart medication management technology, announced the appointment of Lon G. von Hurwitz as chief strategist and senior advisor to the CEO. With over three decades of executive experience in healthcare, marketing, and medical device innovation, von Hurwitz will lead the brand’s next phase as it prepares for its product launch in early 2026.

PillSafe’s product is a wireless smart prescription bottle that offers timed, secure medication dispensing, two-way compliance communication, and safety features that prevent unauthorized access. Co-founders Jim Patton and Dr. John Barr created PillSafe in response to rising rates of prescription drug misuse and the growing need for accountability and oversight across the medical supply chain. The technology enhances medication adherence, reduces prescription diversion, and provides real-time monitoring to support patients, caregivers, and healthcare professionals.

“We welcome Lon as an invaluable strategic leader to help bring PillSafe to market,” said Jim Patton, CEO and co-founder of PillSafe. “His track record in bringing medical technologies to life and navigating investor engagement speaks for itself. He shares our commitment to saving lives and preserving critical healthcare resources.”

“PillSafe is the first product of its kind to bring secure, wireless-enabled prescription bottles from the pharmacy to the home,” von Hurwitz said. “It directly addresses how many people first misuse medications by accessing drugs not meant for them, often from a family member or friend. By dispensing only the correct dose at the correct time, PillSafe introduces a needed layer of control and safety into homes.”

PillSafe plans to launch the product in early 2026 with support from a network of best-in-class development partners and vendors that Pillsafe has assembled to support final engineering and commercialization. The partners include nationally known firms in artificial intelligence, capital market research, government affairs, medical device engineering, pharmacy automation, and predictive healthcare analytics.

The strategy draws on von Hurwitz’s long experience in healthcare product development and marketing. He most recently served as senior commercialization advisor to GE Healthcare, supporting the development of a neuromodulation treatment for diabetes using ultrasound and artificial intelligence.

In 2016, he co-founded Diabetes Treatment Centers International and launched its research institute and center of excellence. Through that work, he secured over $5 million in funding and initiated a clinical research program exploring Pulsatile Insulin Treatment’s (“PIT”) potential to prevent the need for dialysis and kidney transplants. His public policy advocacy brought attention to the treatment from the National Institutes of Health and the Centers for Medicare & Medicaid Services.

Previously, von Hurwitz co-founded World Health Networks and launched a biometric health station network deployed at major international airports. At Lifeclinic International, he led a network of over 23,000 health kiosks located in retail pharmacies across North America, with annual usage exceeding 450 million interactions. He secured pharmaceutical sponsorships to keep these services free to consumers and extended the brand through strategic partnerships with leading cardiology associations.

His marketing and media career spans leadership roles at Sony Entertainment, ABC/Disney, Chrysler, and Carlson Wagonlit Travel. He has worked with major global brands and led campaigns for consumer products, automotive safety, and healthcare technology. His pro bono work includes serving as volunteer marketing chair and later national board chair of Mothers Against Drunk Driving (MADD), and developing the 70^th anniversary telethon for the National Muscular Dystrophy Association.

“I am honored to bring my experience and network to the PillSafe team as we finalize this important product,” von Hurwitz said. “We believe PillSafe has the potential to lower ER visits, reduce addiction risk, and improve accountability across the entire medication lifecycle. With the right partners and strategy in place, we are building a tool that can meaningfully change lives.”

To learn more about PillSafe, visit http://www.pillsafe.org/.

About PillSafe

PillSafe is a pioneering “smart” technology that shifts the standard of care in the pharmaceutical industry with home delivery and patient compliance in response to the opioid epidemic. The company creates prescription compliance by restricting access to medication to only the patient, keeping medication safe from divergence and abuse. PillSafe’s “intelligent” design includes several innovative features that benefit the delivery network from the manufacturer to the pharmacy to the patient. The patented technology includes an electronic label that can increase adherence messaging, two-step verification or active advertising from the manufacturer to the pharmacy to the patient.

While PillSafe is in development of expanding its patented feature set and has not yet been FDA reviewed, it is not currently available for commercial sale.

SOURCE: PillSafe

Related Images

View the original press release on ACCESS Newswire

Global Market Leader in Payment Fraud Prevention Joins Forces With France-Based Sis ID, Where the Combined Entity Will Now Provide Payment Protection in More Markets Around the World

SALT LAKE CITY, UTAH / ACCESS Newswire / June 25, 2025 / Eftsure has announced a significant merger with France-based Sis ID. The deal means the combined entity is now providing payment protection in major markets around the world including the United States, Europe, Australia, New Zealand, India, and China. Global payment verification coverage is expected to be achieved later this year.

The move follows Eftsure’s 2024 expansion into the United States and will see the entity become the world’s largest business payment protection platform, enabling organizations to validate more vendors and protect more business payments in more markets around the world.

The deal comes at a time when businesses are looking to minimize vulnerabilities in a heightened risk environment, with monthly customer data showing the largest ever volume of known fraud attempts since Eftsure was founded in 2014. The FBI’s Internet Crime Complaint Center (IC3) says it recorded nearly $8.5 billion in payment fraud losses between 2022 and 2024.

“Fraud tactics are increasingly sophisticated and difficult to detect, with cybercriminals using artificial intelligence tools to produce realistic fake documents and target businesses at scale,” Eftsure CEO Jon Soldan said. “Eftsure and Sis ID share the common goal of preventing these fraudsters from getting a payout. Combining our resources means we’ll be able to verify more vendors and protect more payments in more markets around the world, all while keeping pace with a rapidly evolving threat landscape.”

Sis ID CEO Laurent Sarrat said the deal made sense because both organizations were focused on helping businesses build cross-border defenses.

“Cybercrime is a global problem and it demands global solutions. Sis ID and Eftsure share a common mission to create collaborative cybercrime solutions that enable business leaders to focus on other priorities,” Sarrat said. “Sis ID has been working for years to deliver global coverage and verify as many payments as possible. Together with Eftsure, we’re well-positioned to offer guaranteed protection for every payment in every market.”

The merger brings together more than 20 years’ experience of business payment fraud prevention, a customer base of more than 3,500 organizations, and support offices across the United States, Australia and France. This positions the merged entity to service a greater number of large enterprises, especially those that manage global supply chains.

“Finding a company so closely aligned in values and vision is rare,” Soldan said. “We share the same perspective on fraud prevention, operational excellence, and what the industry needs to progress. We’re incredibly excited about our shared future and our commitment to serving customers on a global scale.”

Eftsure and Sis ID will continue to drive growth and provide exceptional customer support in their respective regions while working to integrate their brands.

For any media enquiries, please contact:
Gareth Beddoes, Seven Communications
gareth.beddoes@sevencommunications.com.au
0403 463 248

About Eftsure

Founded in 2014, Eftsure is the global market leader in payment fraud prevention. Specifically designed for businesses, our end-to-end solution safeguarded more than $288 billion in B2B payments last year. Powered by cross-checking, we use a variety of verification methods to give businesses greater control over onboarding vendors and making payments, and we back each verified payment with a guarantee. In short, we ensure our customers don’t pay the wrong people.

About Sis ID

Founded in 2016, Sis ID is a French fintech that helps companies detect fraud and attempted fraud both in France and internationally. Created by CFOs and Treasurers from CAC40 companies, Sis ID enables businesses to:

• Make sure they’re paying the right vendor to the correct bank account

• Detect and stay ahead of fraud attempts

• Secure and keep beneficiary records up to date

• Streamline the process from purchase to payment

• Minimize financial fraud risks and pay with confidence

Contact Information

Jessica Lombao
Media Advantage Account Manager
jessica.lombao@issuerdirect.com

SOURCE: Eftsure

View the original press release on ACCESS Newswire

Not for distribution to United States newswire services or for dissemination in the United States

TORONTO, ON / ACCESS Newswire / June 25, 2025 / Northern Superior Resources Inc. (“Northern Superior” or the “Company“) (TSXV:SUP)(OTCQB:NSUPF) is pleased to announce that it has closed its previously announced bought deal financing (see press releases dated June 16, 2025) by issuing 6,500,000 common shares of the Company (the “Common Shares“) at a price of $0.77 per Common Share, for gross proceeds of $5,005,000 (the “Offering“).

Cormark Securities Inc. (the “Underwriter“) acted as sole underwriter and bookrunner of the Offering. In connection with the Offering, the Company paid to the Underwriter a cash commission equal to approximately 6.0% of the gross proceeds of the Offering.

The net proceeds from the Offering will be used for working capital and general corporate purposes.

The Offering was made pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions, as amended and supplemented by Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (the “LIFE Exemption“). The securities issued to Canadian resident subscribers pursuant to the LIFE Exemption will not be subject to a hold period pursuant to applicable Canadian securities laws. A copy of the offering document dated June 16, 2025 prepared by the Company in connection with the LIFE Exemption is available electronically under the Company’s issuer profile on SEDAR+ at www.sedarplus.ca and on the Company’s website at www.nsuperior.com. Final acceptance by the TSX Venture Exchange (the “TSX-V“) of the Offering is subject to the completion of customary post-closing filings.

NQ Investissement Minier

The Company is also pleased to announce that NQ Investissement Minier (“NQIM“) has participated in the Offering. NQIM is a Matagami-based regional investment fund dedicated to mining development in Northern Québec. The fund offers financial support and strategic expertise to exploration companies, with investments guided by a sustainable and responsible approach, promoting positive benefits for local and First Nation communities.

This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act“) or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws, or an exemption from such registration requirements is available. “United States” and “U.S. person” have the meaning ascribed to them in Regulation S under the U.S. Securities Act.

Qualified Person (“QP”)

The technical content and drilling results contained in this news release have been prepared in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101“) and have been reviewed and approved by Ms. Melanie Pichon, P.Geo., Senior Geologist for Northern Superior. Ms. Pichon is a QP under the NI 43-101 and is not considered independent.

About Northern Superior Resources Inc.

Northern Superior is a gold exploration company focused on the Chibougamau Camp in Québec, Canada. The Company has consolidated the largest land package in the region, with total land holdings currently exceeding 62,000 hectares. The main properties include Philibert, Lac Surprise, Chevrier, and Croteau. Northern Superior also owns 56% of ONGold Resources Ltd. (TSXV: ONAU) (OTCQX: ONGRF) which is advancing promising exploration assets in Northern Ontario and Manitoba, including the district scale TPK Project and Monument Bay; Agnico Eagle Mines Limited owns 15% of ONGold Resources Ltd.

The Philibert Project is located 9 km from IAMGOLD Corporation’s Nelligan¹ Gold project. Philibert hosts a maiden 43-101 inferred resource of 48.5 Mt at 1.10 g/t Au for 1,708,800 ounces Au and an indicated resource of 7.9 Mt tonnes at 1.10 g/t Au for 278,900 ounces Au.² Northern Superior holds a majority stake of 75% in the Philibert Project, with the remaining 25% owned by SOQUEM, and retains an option to acquire the full 100% ownership of the project. Chevrier hosts an inferred mineral resource of 15.7 Mt at 1.29 g/t Au for 652,000 ounces Au (underground and open pit) and an indicated mineral resource of 6.4 Mt at 1.26 g/t Au for 260,000 ounces Au.³ Croteau hosts an inferred mineral resource of 11.6 Mt at 1.7 g/t Au for 640,000 ounces Au.⁴ Lac Surprise hosts the Falcon Zone Discovery, interpreted to be the western strike extension of IAMGOLD Corporation’s Nelligan Gold project.

Northern Superior is a reporting issuer in British Columbia, Alberta, Ontario and Québec, and trades on the TSX-V under the symbol SUP and the OTCQB Venture Market under the symbol NSUPF. For further information, please refer to the Company’s website at www.nsuperior.com or the Company’s profile on SEDAR+ at www.sedarplus.ca.

Northern Superior Resources Inc. on Behalf of the Board of Directors

Simon Marcotte, CFA, President and Chief Executive Officer

Contact Information

Katrina Damouni|
Director – Corporate Development
Tel: +44 7795 128583 (Mobile/WhatsApp)
info@nsuperior.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Cautionary Note Regarding Forward-Looking Information

This press release contains forward-looking statements. Forward-looking statements made in this press release include, but are not limited to, the receipt of the TSX-V approval, the use of proceeds of the Offering, the future performance of our business, its operations and its financial performance and condition, as well as management’s objectives, strategies, beliefs and intentions. Forward-looking statements are frequently identified by such words as “may”, “will”, “plan”, “expect”, “anticipate”, “estimate”, “intend” and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of mineral exploration and development, fluctuating commodity prices, competitive risks and the availability of financing, as described in more detail in our recent securities filings available at under the Company’s profile on SEDAR+ at www.sedarplus.ca. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.

View the original press release on ACCESS Newswire

Canalevia^® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for treatment of chemotherapy-induced diarrhea in dogs

Jaguar is exploring the possibility of approval of Canalevia for treatment of general diarrhea in dogs in the EU based on the statistically significant data from a completed study

Diarrhea is one of the most common reasons owners bring their dog to the veterinarian and the second most common reason for visits to the veterinary emergency hospital, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs

Company strategy: In discussions with multiple potential animal health company partners to collaborate to bring Canalevia to regulatory approval and commercialization for general diarrhea globally

SAN FRANCISCO, CA / ACCESS Newswire / June 25, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar), under its Jaguar Animal Health tradename for the veterinary market, today announced that the company plans to pursue approval from the European Medicines Agency’s (EMA) Committee for Veterinary Medicinal Products (CVMP) for Canalevia (crofelemer delayed-release tablets) in the European Union for treatment of general diarrhea in dogs. Canalevia, under the name Canalevia-CA1, is conditionally approved by the U.S. Food and Drug Administration (FDA) as a prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs.

“Jaguar’s primary objective for Canalevia is to identify a partner with which to collaborate to achieve our three parallel goals for the drug: Obtain approval in the EU for Canalevia for treatment of general diarrhea in dogs based on existing Jaguar study data; maintain continuity of availability in the U.S. of Canalevia for treatment of CID in dogs; and to expand the U.S. indication from CID in dogs to treatment of general diarrhea in dogs,” said Lisa Conte, Jaguar’s Founder and CEO. “I’m pleased to report that Jaguar is currently in discussions with multiple potential animal health company partners to collaborate to bring Canalevia to regulatory approval and commercialization for general diarrhea globally.”

Canalevia contains crofelemer, a plant-based botanical prescription drug that modulates chloride channels in the gastrointestinal tract to reduce diarrhea. Importantly, Canalevia is not an antibiotic drug. The overuse and misuse of antibiotics, both in humans and animals, contribute to the development of bacteria that are resistant to antibiotics.

“In the EU, it may be possible to obtain approval of Canalevia for treatment of general diarrhea in dogs based on the results of a study Jaguar completed in 200 dogs with general diarrhea,” Conte said. “While this trial did not meet its stated primary endpoint, the study results are clinically significant when analyzed using an alternate, simplified endpoint, defining treatment success as any dog that had no episodes of diarrhea following the first treatment with either Canalevia or placebo. Using this revised endpoint, the study data shows that dogs treated with Canalevia had significantly better outcomes – with fewer watery stools and significant improvement in fecal scores compared to placebo-treated dogs.”

Jaguar plans to submit a dossier to the European Medicines Agency’s (EMA) Committee for Veterinary Medical Products (CVMP) to outline the results of the updated analysis of the company’s completed study of Canalevia in dogs with general diarrhea. If acceptable to the EMA, the company will then submit a Marketing Authorization Application (MAA) for Canalevia for general diarrhea in dogs. If the application is approved, Canalevia will be marketable for treatment of general diarrhea in dogs in all 27 EU member countries.

Data from the European Pet Food Industry Federation concluded that there were 104 million dogs in Europe in 2022. “We’ve been pleased with the marketplace reception of crofelemer for treatment of CID in dogs in the U.S. and believe there is clearly an unmet medical need for a product for the much larger market of treatment of general diarrhea in dogs – both in the U.S. and the EU,” said Conte. “We estimate that U.S. veterinarians see approximately six million annual cases of acute and chronic diarrhea in dogs, and we look forward to identifying a partner to fund and execute development and commercialization of crofelemer for the treatment of general diarrhea in the U.S. and/or globally. Forging a partnership for this purpose is a key focus of our business development efforts in 2025 and has been designated as a key potential catalyst for the company this year.”

Diarrhea is one of the most common reasons dogs are seen by general practice veterinarians and is the second most common reason for visits to veterinary emergency hospitals, yet there is currently no FDA-approved drug to treat general, non-infectious diarrhea in dogs. According to the American Veterinary Medical Association, there were an estimated 89.7 million dogs in the United States in 2024, with nearly half (45.5%) of U.S. households owning a dog in 2024. Devastating diarrhea-related dehydration can occur rapidly for the animal, and the lack of easy access to outdoor facilities is a significant problem for families living in urban settings with dogs.

Canalevia-CA1, a canine-specific formulation of crofelemer, Jaguar’s novel, oral plant-based drug sustainably harvested from the Croton lechleri tree, is available from multiple leading veterinary distributors in the U.S., including Chewy.

About Conditional Approval and Full Approval

Canalevia-CA1 initially received conditional approval in December 2021 from the FDA for the treatment of CID in dogs. FDA’s conditional approval allows a drug company to legally promote, advertise and sell the animal drug for the labeled uses before proving it meets the “substantial evidence” standard of effectiveness for full approval. The conditional approval is valid for one year, with up to four annual renewals, for a total of five years of conditional approval. To receive a renewal from the FDA, the company must show active progress toward proving “substantial evidence of effectiveness” for full approval. After collecting the remaining effectiveness data, the company then applies to the FDA for full approval. The FDA reviews the application and, if appropriate, fully approves the drug.

About Chemotherapy-induced Diarrhea (CID) in Dogs

According to the American Veterinary Medical Association, approximately 1 in 4 dogs will at some stage in their life develop cancer. Nearly half of dogs over 10 will develop cancer.¹ According to the National Cancer Institute at the National Institutes of Health, roughly 6 million new cancer diagnoses are made in dogs yearly in the U.S.

Due to the increasing number of chemotherapeutic agents, chemotherapy is fast becoming the most widely used cancer treatment in veterinary medicine. Studies have found the incidence of CID to be one of the three most prevalent side effects in dogs undergoing cancer treatment,² and managing side-effects such as diarrhea can be important to maintain successful cancer treatment. More than half of the U.S. veterinarians who responded to a Jaguar-sponsored survey reported that CID interferes with their patients’ chemotherapy treatment plans, indicating an unmet need for an effective product for the treatment of CID.

Canalevia-CA1 is a tablet that can be given orally twice a day and can be used for home treatment of CID in dogs.

About Canalevia^®-CA1

Canalevia-CA1 (crofelemer delayed-release tablets) is the first and only oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea (CID) in dogs. Canalevia-CA1 is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. Canalevia-CA1 is currently conditionally approved by the FDA under application number 141-552. Conditional approval allows for commercialization of the product while Jaguar continues to collect the substantial evidence of effectiveness required for full approval. Jaguar has also received Minor Use in a Major Species (MUMS) designation from the FDA for Canalevia-CA1 to treat CID in dogs. FDA has established a “small number” threshold for minor use in each of the seven major species covered by the MUMS act. The small number threshold is currently 80,000 for dogs, representing the largest number of dogs that can be affected by a disease or condition over the course of a year and still have the use qualify as a minor use.

About Crofelemer

Crofelemer is the only oral FDA-approved prescription drug under botanical guidance. It is plant-based, extracted and purified from the red bark sap of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals, a Jaguar family company, has established a sustainable harvesting program under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for Indigenous communities.

Important Safety Information About Canalevia^®-CA1

For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Canalevia-CA1, visit canalevia.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that it will pursue approval from the EMA’s CVMP for Canalevia in the European Union for treatment of general diarrhea in dogs, Jaguar’s expectation that it will identify a partner to fund and execute development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in dogs in the U.S. and/or globally, Jaguar’s expectation that it may be possible to obtain approval of Canalevia in the EU for treatment of general diarrhea in dogs based on the results of the study Jaguar completed in 200 dogs with general diarrhea, Jaguar’s expectation that it will submit a dossier to the EMA’s CVMP to outline the results of the updated analysis of the company’s completed study of Canalevia in dogs with general diarrhea, Jaguar’s expectation that, if acceptable to the EMA, the company will then submit a MAA for Canalevia for general diarrhea in dogs, and Jaguar’s expectation that, if the MMA is approved, Canalevia will be marketable for treatment of general diarrhea in dogs in all 27 EU member countries. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

¹ “Cancer in Pets.” American Veterinary Medical Association, 2021, https://www.avma.org/resources/pet-owners/petcare/cancer-pets

² Mason SL, Grant IA, Elliott J, Cripps P, Blackwood L. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomised controlled study. J Small Anim Pract. 2014;55:391-398

Contact:

hello@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

The capital will drive market expansion, fuel product innovation, and enable acquisitions to help energy producers power the AI-driven future.

AUSTIN, TX / ACCESS Newswire / June 25, 2025 / Novi Labs (“Novi”), the AI-first energy analytics platform transforming investment decisions across the energy sector, today announced a $35 million investment from Invictus Growth Partners (“Invictus”), a private equity firm focused on backing category-defining companies leveraging artificial intelligence in high-impact industries. Over $50 billion in annual capital allocation decisions from leading energy institutions and investors flow through Novi’s analytics platform, establishing AI-powered analytics as the new standard for institutional energy investment.

The funding will accelerate Novi’s product roadmap, support go-to-market expansion, and enable targeted acquisitions, solidifying Novi’s role as the core intelligence platform for upstream energy investment.

“This investment marks a defining inflection point in our mission to transform how energy development and capital allocation decisions are made”. said Scott Sherwood, CEO of Novi Labs. “We’re moving the industry beyond intuition-based legacy workflows to a future defined by AI and proprietary data. That shift is becoming even more urgent as the rapid buildout of data centers to power AI drives unprecedented energy demand. Novi is uniquely positioned at the center of this transformation, delivering the intelligence platform energy producers rely on to guide billions in capital decisions.”

Powering the Paradigm Shift in Energy Analytics

Traditional tools are falling short in a sector defined by volatility, scale, and operational complexity. Today’s energy producers, investors, and private equity firms require faster, more accurate, and more transparent insights to inform critical decisions.

Novi Labs delivers the only energy analytics platform built natively in the cloud and architected from day one for AI. The platform combines advanced machine learning, exclusive proprietary datasets, and deep reservoir science to produce decision-grade forecasts, enabling smarter capital deployment, optimized well design, and measurable performance gains.

“As AI drives exponential energy consumption, Novi’s platform enables energy producers to scale efficiently and strategically meet that demand,” said John DeLoche, Managing Partner at Invictus. “With a foundation of deep domain knowledge, proprietary datasets, and scientific precision, Novi is reshaping capital allocation in the energy sector. We believe they have built what will become the standard operating system for energy investment, and we are honored to partner with Scott and the entire Novi team.”

Fueling Scale Through Four Strategic Pillars

The $35 million investment will be deployed across four high-impact initiatives designed to accelerate Novi’s growth and category leadership:

• AI-First Product Development: Expanding Novi’s platform to unlock new predictive modeling, analytics, and investment intelligence capabilities.

• Go-to-Market Execution: Scaling commercialization efforts across strategic geographies, verticals, and customer segments.

• Operational Infrastructure: Investing in infrastructure, systems, and talent to support enterprise-grade performance and exponential growth.

• Strategic M&A: With fresh capital and strategic backing, Novi is poised to absorb complementary technology, research, and data players, unlocking new synergies and accelerating innovation.

From Disruption to Domination

As the energy sector faces rising volatility, surging AI-driven demand, and capital constraints across oil & gas, power generation, and renewable energy markets, Novi is uniquely positioned to lead the next era of energy investment intelligence:

• AI That Understands Energy: Domain-specific models trained on proprietary data, not retrofitted to legacy frameworks.

• Energy Data Others Can’t Get: Exclusive proprietary datasets and advanced research methodologies create defensible data moats.

• Research That Shows the Receipts: Proprietary data powers data-driven research that delivers both insights and downloadable underlying datasets to clients, replacing industry guesswork with verifiable intelligence.

About Novi Labs

Novi Labs is the leading AI-first energy analytics platform redefining how energy operators and investors make high-stakes capital decisions. Built on proprietary machine learning, exclusive datasets, and deep reservoir expertise, Novi delivers the industry’s most accurate well-level forecasts and development insights. Many leading E&P operators and mineral owners rely on Novi, with billions in monthly capital decisions flowing through the platform. Novi is headquartered in Austin, Texas.
www.novilabs.com

About Invictus Growth Partners

Invictus Growth Partners is a buyout and growth equity firm that invests in outstanding, bootstrapped, capital-efficient, automation-enabled cloud software, cybersecurity, and fintech companies. The firm is dedicated to supporting companies seeking capital and strategic resources to accelerate their growth.
www.invictusgrowth.com

SOURCE: Novi Labs

View the original press release on ACCESS Newswire

MIAMI, FL / ACCESS Newswire / June 25, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced new in vitro preclinical data generated by Eurofins supporting the therapeutic potential of SKNY-1, a next-generation oral drug candidate being developed by SKNY Pharmaceuticals, Inc. (“SKNY”). MIRA has signed a definitive agreement to acquire SKNY, and the proposed transaction remains subject to regulatory review and shareholder approval.

SKNY-1 is being developed to help individuals lose weight and quit smoking by targeting key biological pathways involved in appetite, addiction, and reward-without triggering the central nervous system (CNS) side effects that have historically limited cannabinoid-based therapies.

“We believe SKNY-1 could be a first-in-class oral therapy for two of the largest and most underserved markets: obesity and nicotine addiction,” said Erez Aminov, CEO of MIRA. “What makes this drug candidate so exciting is its precision-it’s engineered to avoid the psychiatric side effects that doomed earlier drugs in this class, while offering a safe, convenient, once-daily oral option.”

Designed for Selectivity and Safety
Previous CB1-targeting drugs, such as rimonabant (Acomplia®, Sanofi), showed weight loss and metabolic results but were ultimately withdrawn from the market due to serious psychiatric side effects, including depression and suicidal ideation.¹ These effects stemmed from non-selective inhibition of CB1 signaling in the brain.

In contrast, in vitro studies conducted by Eurofins demonstrated that SKNY-1 acts as a biased CB1 modulator-selectively blocking the β-arrestin signaling pathway, which is associated with cravings and compulsive behavior, while preserving G-protein signaling, which is important for emotional and cognitive stability. This selective mechanism is designed to reduce cravings and body weight without disrupting mood.

A Dual Receptor Strategy-Engaging CB2 for Metabolic Support
In addition to CB1 modulation, SKNY-1 also interacts with the CB2 receptor, which plays a critical role in metabolic regulation and inflammation. Eurofins’ in vitro data show that SKNY-1 behaves as a partial CB2 agonist, potentially enhancing fat metabolism, reducing peripheral inflammation and improving insulin sensitivity. This dose-dependent flexibility distinguishes SKNY-1 from earlier CB1-only drugs and may enable a broader therapeutic impact on obesity-related pathways.

“SKNY-1 combines modern pharmacology with real-world practicality,” said Dr. Itzchak Angel, Chief Scientific Advisor at MIRA. “By precisely modulating CB1 and CB2 and supporting dopamine stability, it targets obesity and addiction through multiple, complementary mechanisms while potentially avoiding cannabinoid-related psychiatric side-effects.”

Dopamine Stability Without Stimulant Risk
SKNY-1 also mildly inhibits the MAO-B enzyme, helping regulate dopamine, a neurotransmitter involved in motivation, focus, and reward. Unlike older monoamine inhibitors, SKNY-1 does not inhibit MAO-A, reducing the risk of serotonin-related side effects. Importantly, the compound demonstrated no or minimal antagonist binding to dopamine receptors (D1, D2, D3), further supporting its favorable CNS safety profile.

A Differentiated Alternative to Injectables
While injectable GLP-1 drugs have gained market attention, they are often associated with gastrointestinal side effects and muscle loss. SKNY-1 is being developed as an oral therapy with a profile and expected mechanism that may help preserve muscle mass and improve patient adherence by avoiding injections.

Market Outlook and Strategic Fit
Obesity and smoking remain two of the world’s leading causes of preventable death. The global obesity drug market is projected to surpass $150 billion in value by 2030, and the U.S. smoking cessation market is forecast to grow from $28 billion in 2024 to over $50 billion by decade’s end.

Pending the completion of the proposed acquisition, MIRA believes SKNY-1 could become a cornerstone asset within its pipeline, offering a next-generation solution to two major health challenges. The Company is currently finalizing animal data related to weight loss and nicotine addiction, which will further support its development strategy and future regulatory filings.

MIRA has submitted the required regulatory filings to the U.S. Securities and Exchange Commission (SEC) in connection with the proposed acquisition of SKNY. A shareholder vote will follow in accordance with SEC regulations.

For more information, please visit: www.mirapharmaceuticals.com

About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company’s pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as anxiety, cognitive decline, neuropathic pain, obesity, and addiction.

Cautionary Note Regarding Forward-Looking Statements
This press release and the statements of MIRA’s management related thereto contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA’s current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA’s control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA’s potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA’s programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at www.sec.gov and MIRA’s website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Footnote:
¹ European Medicines Agency. “Acomplia Suspended as Risks Outweigh Benefits.” October 23, 2008.

CONTACT:
Helga Moya
info@mirapharma.com
(786) 432-9792

SOURCE: MIRA Pharmaceuticals

View the original press release on ACCESS Newswire

Tax Identity Theft on the Rise in 2025 – Clear Start Tax Urges Victims to Act Quickly to Limit IRS Damage

IRVINE, CA / ACCESS Newswire / June 25, 2025 / Even after the April 15 deadline, tax identity theft continues to spike in 2025. Clear Start Tax is warning taxpayers to stay alert for one of the most damaging forms of IRS fraud: discovering that someone else has already filed a return in your name. Left unaddressed, this growing issue can delay refunds, trigger audits, and cause years of financial headaches.

The IRS has already flagged a surge in suspicious early-season filings, often from criminals using stolen personal information to claim refunds fraudulently. Unfortunately, many victims don’t realize what has happened until they attempt to file and receive a rejection stating that their return has “already been filed.”

“It’s one of the most stressful tax situations a person can face,” said the Head of Client Solutions at Clear Start Tax. “You’re locked out of your own account, refunds are frozen, and the IRS clock doesn’t stop. But with the right steps, you can regain control.”

Signs Someone Else Filed Using Your Information

If someone uses your Social Security Number to file a tax return, the IRS may process the fraudulent return before you even realize it. Clear Start Tax says to watch for the following red flags:

• Your e-filed return is rejected because a return was already submitted using your SSN.

• The IRS says a refund was issued, but you haven’t filed, and didn’t receive the funds.

• The IRS sends a notice about a suspicious return, new account activity, or a balance due from an unfamiliar filing.

• Your IRS account shows filings or income you don’t recognize.

Tax identity theft can leave you responsible for balances or penalties you didn’t cause. To protect yourself and explore your options under the IRS Fresh Start Program, answer a few quick questions and take the first step toward resolution.

What To Do If You Suspect Tax Identity Theft

The IRS has a formal process for victims of identity theft, but fast action is critical. Clear Start Tax outlines the steps you should take right away if you think someone has filed a return using your Social Security number:

1. File IRS Form 14039 (Identity Theft Affidavit) immediately to alert the IRS of suspected fraud.

2. Respond to any IRS notices – do not ignore them, even if they reference a return you didn’t file.

3. Request a copy of the fraudulent return by submitting Form 4506-F for further investigation.

4. File your real return by paper (not e-file) and include all required identity verification documents.

Clear Start Tax adds that many victims fail to respond quickly enough, which can delay the resolution process or lead to enforced balances for tax debt they don’t actually owe.

How Clear Start Tax Helps Identity Theft Victims

Tax identity theft cases can be difficult to navigate without expert help, especially when IRS systems continue to flag your account. Clear Start Tax supports affected clients by handling the entire response process:

• Managing all IRS correspondence

• Filing Forms 14039 and 4506-F

• Correcting account records and securing account transcripts

• Rebuilding compliance and applying for appropriate taxpayer protections

“We’ve helped clients who were wrongly pursued for years because of identity theft,” said the Head of Client Solutions at Clear Start Tax. “The key is fast documentation, clean records, and expert follow-through – especially when the IRS system flags your account.”

Don’t Wait for the IRS to Sort It Out

Identity theft cases can take months or even years to fully resolve, especially when there’s overlap with back taxes, unfiled returns, or penalties. Victims who act quickly, keep clear documentation, and work with experienced professionals are more likely to avoid long-term damage.

About Clear Start Tax

Clear Start Tax is a full-service tax liability resolution firm that serves taxpayers throughout the United States. The company specializes in assisting individuals and businesses with a wide range of IRS and state tax issues, including back taxes, wage garnishment relief, IRS appeals, and offers in compromise. Clear Start Tax helps taxpayers apply for the IRS Fresh Start Program, providing expert guidance in tax resolution. Fully accredited and A+ rated by the Better Business Bureau, the firm’s unique approach and commitment to long-term client success distinguish it as a leader in the tax resolution industry.

Need Help With Back Taxes?

Click the link below:
https://clearstarttax.com/qualifytoday/

(888) 710-3533

Contact Information

Clear Start Tax
Corporate Communications Department
seo@clearstarttax.com
(949) 535-1627

SOURCE: Clear Start Tax

View the original press release on ACCESS Newswire

Recognized for revolutionizing large file transfer and management workflows in sports, news, and high-volume media production

OTTAWA, ON / ACCESS Newswire / June 25, 2025 / MASV (massive.io), the fastest and most reliable large file transfer platform for media professionals, has been named an IDC Innovator in the IDC Innovators: Media and Entertainment, 2025 report (doc #US52275525, May 2025).

“In today’s market, delivering high-value workflow efficiencies and measurable ROI is essential,” said Alex Holtz, Research Director, Worldwide Media & Entertainment Digital Strategies at IDC. “MASV offers a unique combination of deep cloud and tool integrations, exceptional ease of use, and faster implementation with minimal setup complexity. Their flexible pricing model and ability to work within existing infrastructures further reduce customer risk-making MASV an IDC Innovator in the space.“

According to the report, “MASV serves modern media and entertainment companies with data-intensive applications such as sports and news. Sports demands quick and reliable delivery of high-quality video content from live event footage to highlight reels. Benefits include real-time delivery, efficient remote uploads, and reliability. News agencies constantly operate under immense time constraints, needing to gather and organize breaking stories at lightning speed. Journalists can efficiently upload footage from the field, which MASV automatically categorizes for streamlined newsroom workflows. Reporters with minimal technical expertise can transfer files quickly using drag-and-drop functionality, avoiding technical delays. Automated workflows, such as integrations with Amazon S3 and Slack notifications, ensure that producers and editors access content instantly, accelerating broadcast readiness for time-sensitive stories. MASV simplifies, manages, and supports the transfer of entire archives, individual files up to 15TB, or multi-petabyte data sets such as historical footage or production backups. MASV offers cloud-based scalability with platforms that enable seamless ingestion and distribution of petabyte-scale data directly into storage systems and provides secure, reliable transfers.”

“We’re honored to be recognized as an IDC Innovator in media and entertainment,” said MASV CTO and interim CEO Majed Alhajry. “We’ve built MASV to solve the real problems media teams face today, from shrinking timelines to distributed production teams, and this recognition validates the mission we’re on.”

Download the IDC Innovators Excerpt
To view the MASV excerpt from the IDC Innovators: Media and Entertainment, 2025 report, visit https://massive.io/masv-idc-innovator.

About IDC Innovators:

An IDC Innovators report presents a set of vendors – under $100M in annual revenue at the time of selection – chosen by an IDC analyst within a specific market that offer a new technology, a groundbreaking solution to an existing issue, and/or an innovative business model. It is not an exhaustive evaluation or a comparative ranking of all companies, but rather a document that highlights innovative companies in a specific market segment. IDC INNOVATOR and IDC INNOVATORS are trademarks of International Data Group, Inc.

About MASV

MASV is a cloud-based large file transfer platform designed to orchestrate and secure file movement worldwide to meet fast-paced and nimble workflows. Global media organizations rely on MASV to automatically deliver their large files without any restrictions, allowing them to concentrate on their next big deliverable. To learn more and try MASV for free, visit massive.io or contact team@masv.io.

MASV Press Contact:

Melissa Harding
Grithaus Agency
(e) melissa@grithaus.agency

###

SOURCE: MASV

View the original press release on ACCESS Newswire